Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Man versus beast: pharmacokinetic scaling in mammals.
- J. Mordenti
- Biology, MedicineJournal of pharmaceutical sciences
- 1 November 1986
Analysis of drug pharmacokinetics in numerous species demonstrates that drug elimination among species is predictable and, in general, obeys the power equation Y = aWb.
Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration
The differences in pharmacokinetics and tissue distribution that are noted between the full-length and Fab antibodies in this study identify potential therapeutic approaches that may be exploited in specific disease conditions.
Designing CD4 immunoadhesins for AIDS therapy
A newly-constructed antibody-like molecule containing the gp!20-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes, making it a good candidate for therapeutic use.
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
Clinical and experimental evidence supports a role for overexpression of the HER2 protooncogene in the progression of human breast, ovarian, and non-small cell lung carcinoma, and the hypothesis that p185HER2 present on the surface of overexpressing tumor cells may be a good target for receptor-targeted therapeutics is supported.
Interspecies Scaling of Clearance and Volume of Distribution Data for Five Therapeutic Proteins
- J. Mordenti, Sharon A. Chen, Jerome A. Moore, B. Ferraiolo, James D. Green
- BiologyPharmaceutical Research
- 3 August 1991
Findings indicate that the clearance and volume of distribution of select biomacromolecules follow well-defined, size-related physiologic relationships, and preclinical pharmacokinetic studies provide reasonable estimates of human disposition.
Pharmacokinetic Drug Interaction Studies with Enzalutamide
If a patient requires coadministration of a strong CYP2C8 inhibitor with enzalutamide, then the enzalUTamide dose should be reduced to 80 mg/day, and it is recommended to avoid concomitant use of narrow therapeutic index drugs metabolized by CYP1C9, CYP 2C19, or CYP3A4, as enzyme may decrease their exposure.
Extrapolation of Toxicological and Pharmacological Data from Animals to Humans
Pharmacokinetics, tissue distribution, and expression efficiency of plasmid [33P]DNA following intravenous administration of DNA/cationic lipid complexes in mice: use of a novel radionuclide approach.
Results of the WBAR, TD, MAR, and luciferase assay show that the use of cationic lipids significantly altered the biodistribution and resulting expression of the DNA plasmid, and 33P was shown to be an excellent radionuclide for quantitative WBA and MAR, providing sharp images with less personal hazard and greater ease of handling than 32P.
Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data.
- J. Mordenti
- Biology, ChemistryJournal of pharmaceutical sciences
- 1 July 1985
Three methods of interspecies pharmacokinetic scale-up provided accurate simulations of the human biexponential serum concentration-time profiles for a 1-g iv bolus and a 4-g, 30-min intravenous infusion.
Biological properties of a CD4 immunoadhesin
It is shown that a CD4 immunoadhesin can mediate antibody-dependent cell-mediated cytotoxicity (ADCC) towards HIV-infected cells, although, unlike natural anti-gpl20 antibodies, it does not allow ADCC towards uninfected CD4-expressing cells that have bound soluble gpl20 to the CD4 on their surface.